Baran Züleyha, Çetinkaya Melisa, Baran Yusuf
Laboratory of Molecular Pharmacology, Department of Pharmacology, Anadolu University, Eskişehir, Turkey.
Laboratory of Cancer Genetics, Department of Molecular Biology and Genetics, İzmir Institute of Technology, İzmir, Turkey.
Adv Exp Med Biol. 2025;1474:149-177. doi: 10.1007/5584_2024_824.
The mesenchymal stem/stromal cells (MSCs) are multipotent cells that were initially discovered in the bone marrow in the late 1960s but have so far been discovered in almost all tissues of the body. The multipotent property of MSCs enables them to differentiate into various cell types and lineages, such as adipocytes, chondrocytes, and osteocytes. The immunomodulation capacity and tumor-targeting features of MSCs made their use crucial for cell-based therapies in cancer treatment, yet limited advancement could be observed in translational medicine prospects due to the need for more information regarding the controversial roles of MSCs in crosstalk tumors. In this review, we discuss the therapeutic potential of MSCs, the controversial roles played by MSCs in cancer progression, and the anticancer therapeutic strategies that are in association with MSCs. Finally, the clinical trials designed for the direct use of MSCs for cancer therapy or for their use in decreasing the side effects of other cancer therapies are also mentioned in this review to evaluate the current status of MSC-based cancer therapies.
间充质干/基质细胞(MSCs)是多能细胞,最初于20世纪60年代末在骨髓中被发现,但迄今为止在人体几乎所有组织中都已被发现。MSCs的多能特性使其能够分化为各种细胞类型和谱系,如脂肪细胞、软骨细胞和骨细胞。MSCs的免疫调节能力和肿瘤靶向特性使其在癌症治疗的细胞疗法中发挥关键作用,但由于需要更多关于MSCs在肿瘤串扰中争议性作用的信息,在转化医学前景方面进展有限。在本综述中,我们讨论了MSCs的治疗潜力、MSCs在癌症进展中所起的争议性作用以及与MSCs相关的抗癌治疗策略。最后,本综述还提到了为直接使用MSCs进行癌症治疗或用于减轻其他癌症治疗副作用而设计的临床试验,以评估基于MSCs的癌症治疗的现状。